CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Citing CVS spokesperson David Whitrap, Bloomberg News reported that “Zepbound will be excluded” in health plans using ... in those plans could switch to Wegovy, while exceptions will be ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

CVS Health reported $1.8 billion in net income for the first quarter, a 58.5% leap, as revenue increased 7% to $94.6 billion.

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... while membership increased by 1.1%. For health services, which include CVS Caremark, revenue increased 7.9% to $43.46 billion ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...